Some news

Now online! DrugMap: A quantitative pan-cancer analysis of cysteine ligandability dlvr.it/T5snQv

Congratulations to @ScorpionTx scientific founder and collaborator, Liron Bar-Peled on the publication of this important milestone in chemical proteomics and cancer.

Scorpion raises $150M with sights on the next wave of targeted therapies endpts.com/scorpion-raise…

As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel. fiercebiotech.com/biotech/scorpi…

@ScorpionTx announced the closing of their $150 Million Series C financing, advancing their growing precision oncology pipeline and redefining the outcomes for people living with cancer. Congratulations, Scorpion! Learn more: bit.ly/3XZsgHM #VidaPortfolio

Congrats to the drug hunters at scorpiontx for the sale of their PI3K program to $LLY! Compelling clinical data is the coin of the realm. Kudos to Adam Friedman and the rest of the team! investor.lilly.com/news-releases/… Excited to see "Chapter 2" unfold with the new spinout!

The Scorpion Therapeutics story is a great one for many reasons, but it’s a fantastic story about long term relationships and the importance of patient people-centric investing. CEO Adam Friedman joined Atlas over 15 years ago in 2010 as an EIR, working across several Atlas

Today marks the launch of Antares Therapeutics, spinout of Scorpion Tx, following its acquisition earlier this year. I am grateful to the entire Antares team for their ingenuity & dedication to patients as we continue our mission to bring transformative medicines to patients.

We’re thrilled to share that Antares has been nominated for a #NEVYs25 Emerging Company of the Year Award in Therapeutics! Thank you to The New England Venture Capital Association for recognizing our commitment to transforming patient lives through pioneering precision medicines. Learn more about the NEVYs: